Overview

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Status:
Unknown status

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer

Phase:

Phase 2

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Treatments:

Apatinib
Capecitabine